New Gene Therapy for Hearing Loss Approved
The Food and Drug Administration (FDA) has approved a groundbreaking therapy for genetic hearing loss. This new treatment, named Otarmeni (lunsotogene parvec-cwha), is the first of its kind that uses a combination of two harmless viruses to deliver healing genes directly into cells.
The FDA praised this innovative therapy as a major advancement, highlighting its potential benefits for both children and adults who experience “severe to profound” hearing loss related to the OTOF gene.
In clinical trials published in The New England Journal of Medicine in 2025, it was shown that the therapy improved hearing for some patients with OTOF-related deafness. Specifically, three out of twelve participants were able to hear better, suggesting that the treatment could help restore natural hearing.
This approval is particularly noteworthy as it marks the first effective treatment for OTOF-related deafness. Additionally, it is the sixth drug approved under the FDA’s National Priority Voucher pilot program, which aims to speed up the process for therapies that address rare diseases.
FDA Commissioner Marty Makary stated, “Today’s approval represents an important achievement in the fight against genetic hearing loss.” He emphasized that the pilot program allows the FDA to review complex treatments more swiftly.
Otarmeni is given through a surgical procedure that delivers the gene therapy directly into the inner ear using a small needle. The therapy aims to introduce a healthy version of the OTOF gene to certain cells in the inner ear, helping restore a protein called otoferlin, which is essential for transmitting sound signals to the brain.
While the treatment shows promise, it does come with potential side effects such as middle ear infections, nausea, dizziness, and pain from the procedure. It is designed for patients who still have functioning outer hair cells and have not had cochlear implants in the same ear.
To discuss the rollout of this new treatment, the FDA has announced a public meeting scheduled for June 4.
